Polaris Venture Management Co. V, L.L.C.
CIK 1439589 · last filed 2020-05-06
Polaris Venture Management Co. V, L.L.C. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 6 companies since 2014. The most recent filing, for LYRA, was dated May 6, 2020. Across all open-market trades the lifetime net is −$95.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $32.3M across reported positions. The firm reports its address in Boston, MA. 57 SEC filings were submitted jointly with Polaris Venture Partners Entrepreneurs' Fund V, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$32.28M
6
9
-$95.40M
Filer Profile
10TH FLOOR
BOSTON, MA 02210
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Lyra Therapeutics, Inc. (LYRA) Delisted | 10%+ Owner | 21,245 | $0.70 | $14.9K | $5.92M | 1 | 2020-05-06 |
| PHR | 10%+ Owner | 3,101,386 | $10.15 | $31.48M | -$61.19M | 1 | 2019-12-18 |
| CDLX | 10%+ Owner | 219,748 | $3.30 | $725.2K | -$33.40M | 4 | 2019-06-11 |
| T2 Biosystems, Inc. (TTOO) Delisted | 10%+ Owner | 16 | $0.00 | $0 | -$2.49M | 1 | 2015-07-14 |
| LIFE | 10%+ Owner | 2,332 | $34.30 | $80.0K | $0 | 1 | 2015-05-14 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 258,111 | $0.00 | $155 | -$4.24M | 1 | 2014-08-12 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-06 | Lyra Therapeutics, Inc. (LYRA) Delisted | Mixed | +7,705,964 | $7.00M | EDGAR |
| 2019-12-18 | PHR | Sell (S) | −2,499,847 | -$61.19M | EDGAR |
| 2019-06-11 | CDLX | Sell (S) | −500,000 | -$12.81M | EDGAR |
| 2019-06-06 | CDLX | Sell (S) | −376,420 | -$9.07M | EDGAR |
| 2019-05-30 | CDLX | Sell (S) | −500,000 | -$11.52M | EDGAR |
| 2018-02-15 | CDLX | Conv (C) | +13,181,310 | $0 | EDGAR |
| 2015-07-14 | T2 Biosystems, Inc. (TTOO) Delisted | Sell (S) | −149,990 | -$2.49M | EDGAR |
| 2015-05-14 | LIFE | Conv (C) | +9,139,960 | $0 | EDGAR |
| 2014-08-12 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Sell (S) | −318,970 | -$4.24M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.